Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)

SHA:603590 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	870.34	824.43	917.75	851.05	693.03	808.64
Other Revenue	0.97	0.97	2.26	15.68	116.76	-
Revenue	871.31	825.4	920.01	866.73	809.78	808.64
Revenue Growth (YoY)	2.96%	-10.28%	6.15%	7.03%	0.14%	-24.14%
Cost of Revenue	85.71	86.26	101.05	126.65	105.76	59.25
Gross Profit	785.59	739.14	818.96	740.07	704.02	749.4
Selling, General & Admin	567.88	553.76	583.28	525.88	479.34	535.52
Research & Development	52.7	54.94	94.91	86.78	102.27	93.11
Other Operating Expenses	8.38	6.75	5.64	6.04	8.69	11.82
Operating Expenses	643.9	620.37	689.42	620.56	591.51	637.72
Operating Income	141.69	118.77	129.54	119.51	112.51	111.67
Interest Expense	-7.18	-6.16	-2.78	-0.86	-1.41	-0.42
Interest & Investment Income	25.94	30.98	19.33	18.52	24.57	59.96
Currency Exchange Gain (Loss)	-1.29	-1.29	0.5	0.26	0.31	-0
Other Non Operating Income (Expenses)	-13.75	-1.56	-1.7	-0.36	1.58	-2.04
EBT Excluding Unusual Items	145.4	140.74	144.9	137.06	137.57	169.17
Impairment of Goodwill	-97.64	-97.64	-	-	-	-
Gain (Loss) on Sale of Investments	-1.28	-0.49	-12.78	-7.65	35.64	1.36
Gain (Loss) on Sale of Assets	0.11	-0.03	-0.13	-0.01	0	-0.08
Asset Writedown	-7.77	-7.77	-	-4.06	-	-
Other Unusual Items	4.05	4.05	-9.26	14.98	15.64	37.57
Pretax Income	42.86	38.86	122.73	140.32	188.86	208.02
Income Tax Expense	10.55	17.33	-64.84	16.42	21.42	24.67
Earnings From Continuing Operations	32.31	21.53	187.57	123.89	167.44	183.35
Minority Interest in Earnings	24.81	20.69	-37.12	-22.4	-19.46	0
Net Income	57.12	42.22	150.45	101.49	147.99	183.36
Net Income to Common	57.12	42.22	150.45	101.49	147.99	183.36
Net Income Growth	-50.24%	-71.94%	48.24%	-31.42%	-19.29%	-31.09%
Shares Outstanding (Basic)	157	156	157	156	157	159
Shares Outstanding (Diluted)	157	156	157	156	157	159
Shares Change (YoY)	0.03%	-0.23%	0.37%	-0.82%	-1.26%	-0.53%
EPS (Basic)	0.36	0.27	0.96	0.65	0.94	1.15
EPS (Diluted)	0.36	0.27	0.96	0.65	0.94	1.15
EPS Growth	-50.26%	-71.88%	47.69%	-30.85%	-18.26%	-30.72%
Free Cash Flow	62.22	68.22	98.44	23.38	-108.43	8.03
Free Cash Flow Per Share	0.40	0.44	0.63	0.15	-0.69	0.05
Dividend Per Share	0.600	0.600	0.300	0.200	0.300	0.350
Dividend Growth	100.00%	100.00%	50.00%	-33.33%	-14.29%	-30.00%
Gross Margin	90.16%	89.55%	89.02%	85.39%	86.94%	92.67%
Operating Margin	16.26%	14.39%	14.08%	13.79%	13.89%	13.81%
Profit Margin	6.56%	5.12%	16.35%	11.71%	18.27%	22.68%
Free Cash Flow Margin	7.14%	8.27%	10.70%	2.70%	-13.39%	0.99%
EBITDA	163.77	146.73	165.35	151.54	144.29	141.71
EBITDA Margin	18.80%	17.78%	17.97%	17.48%	17.82%	17.52%
D&A For EBITDA	22.08	27.96	35.8	32.03	31.78	30.04
EBIT	141.69	118.77	129.54	119.51	112.51	111.67
EBIT Margin	16.26%	14.39%	14.08%	13.79%	13.89%	13.81%
Effective Tax Rate	24.62%	44.60%	-	11.70%	11.34%	11.86%
Revenue as Reported	871.31	825.4	920.01	866.73	809.78	808.64
Advertising Expenses	-	-	-	32.55	350.29	448.58

Source: S&P Global Market Intelligence. Standard template. Financial Sources.